Clinical Features and Long-Term Outcomes of Systemic Lupus Erythematosus
The clinical spectrum of systemic lupus erythematosus (SLE) is highly heterogeneous, ranging from mild disease, which can be limited to skin and joint involvement, to life-threatening conditions with renal impairment, severe cytopenias, central nervous system disease, and thromboembolic events. Apar...
Saved in:
| Format: | Online |
|---|---|
| Language: | English |
| Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Subjects: | |
| Online Access: | ONIX_20230202_9783036561103_23 |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1869516076494094336 |
|---|---|
| collection | Directory of Open Access Books |
| description | The clinical spectrum of systemic lupus erythematosus (SLE) is highly heterogeneous, ranging from mild disease, which can be limited to skin and joint involvement, to life-threatening conditions with renal impairment, severe cytopenias, central nervous system disease, and thromboembolic events. Apart from the host genetics, several environmental factors, such as sunlight, infections, drugs, and probably hormonal factors, can trigger the onset of symptoms related to SLE. Despite significant advances in our understanding of the pathophysiology and optimization of medical care, patients with SLE still have significant rates of premature mortality and many patients experience severe disease with increased risk of sustaining organ damage and having a reduced health-related quality of life. The development of effective drugs that can induce remission or low disease activity, the unanimous use of definitions of remission and low or high disease activity, flare, and response to therapy, the identification of non-invasive biomarkers of disease activity and long-term outcomes, and the implementation of SLE patients’ perspectives as an integral part of the clinical assessment constitute only a few of the many unmet needs in the field of SLE. |
| format | Online |
| id | doab-20.500.12854ir-96622 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2023 |
| publishDateRange | 2023 |
| publishDateSort | 2023 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-966222024-03-30T23:21:50Z Clinical Features and Long-Term Outcomes of Systemic Lupus Erythematosus Sjöwall, Christopher Parodis, Ioannis systemic lupus erythematosus quality of life cross-sectional studies surveys and questionnaires rheumatoid arthritis fatigue pain psychosocial disease activity health-related quality of life patient-reported outcomes clinical follow-up outcome measures abnormal liver function tests autoimmune liver diseases autoimmune hepatitis hepatic involvement liver biopsy primary biliary cholangitis COVID-19 hydroxychloroquine glucocorticoids epidemiology Systemic Lupus Erythematosus outcome mortality survival end-stage renal disease cancer cardiovascular disease infections neoplasm hospital admissions medication adherence compliance patient perspective qualitative research classification cluster analysis laboratory linear discriminant analysis genetics chronic damage polymorphisms TNFSF4 MIR1279 Ki/SL proteasome autoantibodies lupus SLE Sjögren syndrome flare damage long disease duration trajectories remission low disease activity comorbidities mood disorders low-disease activity patient outcome Afro-Caribbean systemic lupus lupus nephritis long-term prognosis dehydroepiandrosterone SLEDAI-2K n/a thema EDItEUR::M Medicine and Nursing The clinical spectrum of systemic lupus erythematosus (SLE) is highly heterogeneous, ranging from mild disease, which can be limited to skin and joint involvement, to life-threatening conditions with renal impairment, severe cytopenias, central nervous system disease, and thromboembolic events. Apart from the host genetics, several environmental factors, such as sunlight, infections, drugs, and probably hormonal factors, can trigger the onset of symptoms related to SLE. Despite significant advances in our understanding of the pathophysiology and optimization of medical care, patients with SLE still have significant rates of premature mortality and many patients experience severe disease with increased risk of sustaining organ damage and having a reduced health-related quality of life. The development of effective drugs that can induce remission or low disease activity, the unanimous use of definitions of remission and low or high disease activity, flare, and response to therapy, the identification of non-invasive biomarkers of disease activity and long-term outcomes, and the implementation of SLE patients’ perspectives as an integral part of the clinical assessment constitute only a few of the many unmet needs in the field of SLE. 2023-02-02T16:25:20Z 2023-02-02T16:25:20Z 2023 book ONIX_20230202_9783036561103_23 9783036561103 9783036561097 https://directory.doabooks.org/handle/20.500.12854/96622 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/6567 https://mdpi.com/books/pdfview/book/6567 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-6109-7 10.3390/books978-3-0365-6109-7 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036561103 9783036561097 208 Basel open access |
| spellingShingle | systemic lupus erythematosus quality of life cross-sectional studies surveys and questionnaires rheumatoid arthritis fatigue pain psychosocial disease activity health-related quality of life patient-reported outcomes clinical follow-up outcome measures abnormal liver function tests autoimmune liver diseases autoimmune hepatitis hepatic involvement liver biopsy primary biliary cholangitis COVID-19 hydroxychloroquine glucocorticoids epidemiology Systemic Lupus Erythematosus outcome mortality survival end-stage renal disease cancer cardiovascular disease infections neoplasm hospital admissions medication adherence compliance patient perspective qualitative research classification cluster analysis laboratory linear discriminant analysis genetics chronic damage polymorphisms TNFSF4 MIR1279 Ki/SL proteasome autoantibodies lupus SLE Sjögren syndrome flare damage long disease duration trajectories remission low disease activity comorbidities mood disorders low-disease activity patient outcome Afro-Caribbean systemic lupus lupus nephritis long-term prognosis dehydroepiandrosterone SLEDAI-2K n/a thema EDItEUR::M Medicine and Nursing Clinical Features and Long-Term Outcomes of Systemic Lupus Erythematosus |
| title | Clinical Features and Long-Term Outcomes of Systemic Lupus Erythematosus |
| title_full | Clinical Features and Long-Term Outcomes of Systemic Lupus Erythematosus |
| title_fullStr | Clinical Features and Long-Term Outcomes of Systemic Lupus Erythematosus |
| title_full_unstemmed | Clinical Features and Long-Term Outcomes of Systemic Lupus Erythematosus |
| title_short | Clinical Features and Long-Term Outcomes of Systemic Lupus Erythematosus |
| title_sort | clinical features and long term outcomes of systemic lupus erythematosus |
| topic | systemic lupus erythematosus quality of life cross-sectional studies surveys and questionnaires rheumatoid arthritis fatigue pain psychosocial disease activity health-related quality of life patient-reported outcomes clinical follow-up outcome measures abnormal liver function tests autoimmune liver diseases autoimmune hepatitis hepatic involvement liver biopsy primary biliary cholangitis COVID-19 hydroxychloroquine glucocorticoids epidemiology Systemic Lupus Erythematosus outcome mortality survival end-stage renal disease cancer cardiovascular disease infections neoplasm hospital admissions medication adherence compliance patient perspective qualitative research classification cluster analysis laboratory linear discriminant analysis genetics chronic damage polymorphisms TNFSF4 MIR1279 Ki/SL proteasome autoantibodies lupus SLE Sjögren syndrome flare damage long disease duration trajectories remission low disease activity comorbidities mood disorders low-disease activity patient outcome Afro-Caribbean systemic lupus lupus nephritis long-term prognosis dehydroepiandrosterone SLEDAI-2K n/a thema EDItEUR::M Medicine and Nursing |
| topic_facet | systemic lupus erythematosus quality of life cross-sectional studies surveys and questionnaires rheumatoid arthritis fatigue pain psychosocial disease activity health-related quality of life patient-reported outcomes clinical follow-up outcome measures abnormal liver function tests autoimmune liver diseases autoimmune hepatitis hepatic involvement liver biopsy primary biliary cholangitis COVID-19 hydroxychloroquine glucocorticoids epidemiology Systemic Lupus Erythematosus outcome mortality survival end-stage renal disease cancer cardiovascular disease infections neoplasm hospital admissions medication adherence compliance patient perspective qualitative research classification cluster analysis laboratory linear discriminant analysis genetics chronic damage polymorphisms TNFSF4 MIR1279 Ki/SL proteasome autoantibodies lupus SLE Sjögren syndrome flare damage long disease duration trajectories remission low disease activity comorbidities mood disorders low-disease activity patient outcome Afro-Caribbean systemic lupus lupus nephritis long-term prognosis dehydroepiandrosterone SLEDAI-2K n/a thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20230202_9783036561103_23 |